Patients quality of life following induction of oral immunotherapy for food allergyAlthough patients' quality of life improves upon completion of oral immunotherapy (OIT), little is known about the influences of the treatment process itself. During treatment, patients and their parents endure many difficulties, including repeated exposures to an allergen they are used to avoid, a process which some find aversive, as well as reactions, some of which are severe requiring injectable epinephrine. The initial induction phase might be particularly significant. It is during this week that the maximal tolerated dose of each patient is established, a dose which represents the severity of the patient's allergy and which predicts the course of his treatment, including its length and odds for success. Thus, the initial induction week might adversely affect patients' quality of life.In this study, Epstein Rigbi et al.(1) investigated the factors affecting quality of life in patients during the first week of OIT for food allergy. For this purpose, the Food Allergy Quality of Life Questionnaire for parents of children aged 0-12 years was translated into Hebrew and validated. The questionnaire was then completed by 119 parents of children undergoing OIT for cow's milk, egg and peanut allergy, at the end of the first induction. In addition to pre-OIT reactions' severity, a lower maximal tolerated starting dose particularly in school-aged children, was found to adversely affect patients' quality of life, This study is the first to examine the quality of life of patients during the process of OIT. The results emphasize that some aspects of the process itself might negatively affect patient's quality of life. This should be recognized by OIT programmes as it might lead to patient non-compliance with the treatment. It is of interest to examine how patients' quality of life continues to change throughout the treatment process and which factors mostly affect it.